# CEO turned informant: How the FDA built a case against executives promising cheap medications

- URL: https://talkfuse.com/story/ceo-turned-informant-how-the-fda-built-a-case-against-executives-promising-cheap-medications/
- Published: 2026-11-18T21:07:14+00:00
- Updated: 2026-11-19T11:56:10+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/18/fda-canarx-case-informant.html
- Topics: Business, Companies

## Key points

- ScriptSourcing’s CEO became a co-operating witness in the FDA’s CANARX investigation.
- Records showed about 16,549 prescriptions dispensed through dealings with CANARX.
- The affidavit describes alleged patient harm and recorded calls about import routes.

## Summary

The FDA’s investigation into CANARX grew from scrutiny of ScriptSourcing, a Florida company that marketed imported prescription medicines to employer health plans. Its chief executive, Gary Becker, became a government co-operating witness and supplied information about CANARX and its executives, helping build a case over alleged illegal drug imports.

An affidavit by FDA investigator Dustin Dobbs says ScriptSourcing had been under scrutiny since at least 2022 and describes two alleged patient-harm incidents involving medicines it sourced, including misbranded Mounjaro and a counterfeit drug. A spreadsheet provided by ScriptSourcing recorded about 16,549 prescription medicines dispensed through financial dealings with CANARX from 2021 to 2026. The affidavit also cites recorded calls in which John and Bob Howard allegedly discussed import routes and their understanding that the medicines could not legally enter the US; one shipment under preparation included Neupro, used for Parkinson’s disease and restless legs syndrome.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
